TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 36397669.
- Also identified by DOI 10.1002/cncr.34535 and PMC identifier 11938810.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
TP53-altered myelodysplastic syndrome with excess blasts and TP53-altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for clinical trials and allow a focus on treating the patient for a genetically defined disorder rather than one based on an arbitrary blast threshold.
Medical subject headings
- Myelodysplastic Syndromes
- Leukemia, Myeloid, Acute